Subsequent events - Zentalis Pharmaceuticals, Inc. License Agreement (Details) - Subsequent events - License agreement with Zentalis Pharmaceuticals, Inc $ in Millions	Jan. 05, 2024 USD ($)
Subsequent events
Upfront consideration paid in cash	$ 15
Upfront consideration paid in shares	$ 20
Trailing period of shares	30 days
Maximum amount payable	$ 150
Additional amount payable	$ 25